| | Price Trend | Performance | Ratios | Snapshot

Sun Pharmaceutical Industries | 82.5% [High Score] |Shares Pledge: [1.97%]

Is the company worth investing in (now)?: I'll Buy [Price is nearly undervalued & Fundamentals are Reasonable]

1,702.80

73.90 | 4.54%

Price

Healthcare - Branded Medicines

1,411.64

Overvalued

Intrinsic Value

Top | Performance | Ratios | Snapshot

Price Trend

2%
Price 14 Day

Past → Today

-1%
Price 30 Day

Past → Today

1%
Price 90 Day

Past → Today

Overview
How is the Stock? Price: Reasonably Valued & Fundamentals Only Reasonable
Overall Score (Remark) 82.5% [High Score] |Shares Pledge: [1.97%]
Is It A Fundamentally Strong Company? Fundamentals Only Reasonable
Fundamental Strength Score [out of 5] 3.67
Overview
6.79%
Last 10Y Price Trend

Past → Today

-2.61%
P/E

Past → Today

Quick Observations #1
  1. The operating revenue has grown consistently in the last 5 years
  2. Positive @11.15% p.a. in the last 5 years
  3. Reasonably consistent in the last 5 years
  4. Maintained a positive EBITDA Margin of 27.53% in the last 5 years
  5. EBITDA Margin has improved in the last 5 years @16.1% p.a.
Quick Observations #2
  1. Reasonably consistent in the last 5 years
  2. Maintained a positive PAT Margin of 18.88% in the last 5 years
  3. PAT Margin has improved in the last 5 years @22.72% p.a.
  4. Reasonably consistent in the last 5 years
  5. Maintained a positive ROE of 15.14% in the last 5 years
  6. ROE has improved in the last 5 years @25.18% p.a.
Quick Observations #3
  1. Total asset has grown at 6.35% p.a. in the last 5 Years
  2. The company has been consistently solvent in the last 5 years
  3. The company has reduced it's D/E ratio in the last 5 years
  4. Maintained an average D/E ratio of 0.05 in the last 5 years
Quick Observations #4
  1. Consistently liquid in the last 5 years
  2. Improved in the last 5 years
  3. Maintained an average current ratio of 2.3 in the last 5 years
  4. Consistently Positive
Price Valuation
Is It An Undervalued Stock? Reasonably Valued
Price Valuation Score [out of 5] 4.72
Price ₹1,702.80
Intrinsic Value ₹1,411.64
P/E 37.43
EV/EBITDA 21.95
P/FCF 701.86
Current Price vs. Intrinsic Value (IV)
Current Price

₹1,702.8

Intrinsic Value

₹1,411.6438

Overvalued

Sample Data. Subscribe to view actual data.
Share Holding Pattern
Profitability
Is It A Profitable Company? Reasonably Profitable
Profitability Score [out of 5] 3.88
WAAC 13.32%
ROCE-5Y 14.41%
Free Cash Flow Positive
Operating Profit 13,229.00
Net Profit 10,912.00
Profitability
Growth
Is It A Growing Company? Growth Rate Is Above Average
Growth Score [out of 5] 3.94
Reserves Growth 9.00%
Total Asset Growth 6.00%
Operating Revenue Growth 11.00%
Net Profit Growth 37.00%
Operating Cash Flow Growth 18.00%
FCF Growth (5Y) 17.00%
Sustainable Growth 12.00%
51.83%
EPS

Past → Today

Financial Health
Is The Company Financially Healthy? Financial Health Is Reasonably Strong
Financial Health Score [out of 5] 4.24
Is the company liquid? Yes. Its Liquidity is Very High
Is the ROE growing? No. The Trend is Falling
Is the ROE high? Yes. Its High
Company is reducing debt? Yes. D/E Ratio is Decreasing
Company's D/E ratio is low? Yes. D/E Ratio is Very Low
Is the ROCE growing? No. It is Falling
Is the ROCE High? Yes. It is Moderately High
Financial Health
Quality of Management
How Is The Quality Of The Management? Highly Quality Management
Management Quality Score [out of 5] 4.01
Operating profit is Growing? Yes. The Operating Profit has grown
Operating profit Consistently Growing? Yes. The Operating Profit has Consistently Grown
EPS is Growing? Yes. The EPS has grown
EPS Consistently Growing? No. The EPS Growth in not Consistent
Capital Utilization is Proper? No. Capital Use is Not Proper
Reinvested Capital Meets The Purpose? Yes. It is Very Good
Is It Overpaying The Dividends? Yes. It can Afford, But it can consdier Reinvestment
Operating Profit Margin
Competitive Moat
Does The Company Has Competitive Moat? Moat Is Only Reasonably Wide
Moat Score [out of 5] 3.98
Competitors
NameM.Cap (₹ Cr.)Revenue (₹ Cr.)PAT (₹ Cr.)TTM EPSTTM P/EP/BROEOverall Score (%)
Torrent Pharmaceuticals136,933.5211,539.361,911.2563.2363.9718.0428.19Subscribe to view
Sun Pharmaceutical Industries408,388.3354,543.4810,980.1045.5037.425.6515.11Subscribe to view
Lupin99,850.4422,903.723,306.2694.7423.095.8025.13Subscribe to view
Dr. Reddy's Laboratories102,707.2133,741.205,703.5066.8718.473.0616.59Subscribe to view
Cipla106,901.6728,409.495,291.0567.5419.603.4317.44Subscribe to view
Theme Ranks
Theme Rank Total Stocks Theme Rank Total Stocks
Best Stocks 9 1,347 Fast Growing Stocks 135 1,356
Profitable Stocks 38 1,339 Dividend Paying Stocks 48 364
Blue-Chip Stocks 12 99 Low PE Stocks 4 145
Debt Free Stocks 7 855 Buffet Type Stocks 65 1,355
Fundamentally Strong Stocks 54 1,356 High Return Stocks 400 1,367
Undervalued Stocks 70 1,342 Penny Stocks 0 253
Profitable & Growing Stocks 0 125
Price Summary
Today's High Today's Low 52W High 52W Low
1,725.0 1,671.05 1,850.95 1,547.25
Recent Results
Market Cap (Cr) Revenue (Cr) Net Profit (Cr) Net Worth (Cr)
408,388.33 54,543.48 10,980.10 72,218.02
D/E Current Ratio ROE (%) ROCE (%)
0.03 2.89 15.11 20.77
Valuation & Growth
P/E P/B Div.Yield (%) PEG (%)
37.43 5.65 0.94 6.44
EPSG-3Y (%) EPSG-3Y (%) 3M-Return (%) 1Y-Return (%)
22.92 51.83 -1.02 -2.89
About Company

Sun Pharmaceutical Industries Ltd. is the fifth largest speciality generic pharmaceutical company in the world. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics branded generics complex or difficult to make technology intensive products over-the-counter (OTC) products anti-retrovirals (ARVs) Active Pharmaceutical Ingredients (APIs) and intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage forms including tablets capsules injectables inhalers ointments creams and liquids. The products cater to a vast range of therapeutic segments covering psychiatry anti-infectives neurology cardiology orthopaedic diabetology gastroenterology ophthalmology nephrology urology dermatology gynaecology respiratory oncology dental and nutritionals.

Top | Price Trend | Ratios | Snapshot

Performance Summary

8.0%

Net Sales

Past → Today

8.29%

Total Income

Past → Today

29.11%

Operating Profit

Past → Today

26.22%

PAT

Past → Today

8.51%

Net Worth

Past → Today

26.58%

EPS

Past → Today

2%

Last 14D Price Trend

Past → Today

-1%

Last 30D Price Trend

Past → Today

1%

Last 90D Price Trend

Past → Today

4%

Last 180D Price Trend

Past → Today

-3%

Last 1Y Price Trend

Past → Today

18.86%

Last 3Y Price Trend

Past → Today

24.48%

Last 5Y Price Trend

Past → Today

0%

EV/EBIDTA

Past → Today

Top | Price Trend | Performance | Snapshot

Ratios

Liquidity Ratios
IndicatorUnitTTMMar 25Mar 24Mar 23Mar 22Mar 21
Current Ratio-2.892.892.562.002.041.89
Quick Ratio-2.332.331.981.481.511.33
Cash Ratio-0.620.620.620.290.290.40
Solvency Ratios
IndicatorUnitTTMMar 25Mar 24Mar 23Mar 22Mar 21
Current Debt to Inventory-1.781.781.721.891.911.79
Current Debt to Equity-0.030.030.040.110.020.07
D / E-0.030.030.040.110.020.07
Interest Coverage Ratio-52.2760.4447.5055.7036.1920.79
Efficiency Ratios
IndicatorUnitTTMMar 25Mar 24Mar 23Mar 22Mar 21
Fixed Asset Turnover Ratio-2.712.592.432.122.251.99
Gross Margin%80.4579.5678.0175.7073.2274.06
Operating Margin%22.3122.8620.5620.389.546.28
EBITDA Margin%29.8330.3627.8527.2017.0614.62
PAT Margin%18.3420.1319.3519.238.616.65
Op.Cash Flow Margin%25.6026.7625.0211.3023.2418.42
ROA%11.3411.9211.2910.604.883.38
ROE%14.4715.2015.1515.297.094.92
ROCE%19.3118.9216.5415.758.765.71
ROIC%8.499.6510.4210.413.132.07
Price Valuation Ratios
IndicatorUnitTTMMar 25Mar 24Mar 23Mar 22Mar 21
P/E-36.9338.0942.8329.4871.5252.67
PEG-26.472.351.720.172.5652.67
EV/EBITDA-22.1722.7916.5318.5120.9212.74
Price to Sales-7.027.364.895.103.762.00
P/B-5.345.363.724.003.031.44
Dividend Yield%0.940.931.221.131.492.33
P/FCF--222.21-222.7829.8018.17-69.95-10.28
FCF/Sales--0.14-0.140.030.02-0.12-0.03
Earnings Yield%3.793.714.944.273.264.60
Top | Price Trend | Performance | Ratios

Snapshot

Quarterly Report
IndicatorUnitTTMDec '25Sep '25Jun '25Mar '25Dec '24
SalesRs. Cr.56,807.0015,520.0014,478.0013,851.0012,958.0013,675.00
Other IncomeRs. Cr.2,123.00578.00469.00464.00612.00465.00
Op. ProfitRs. Cr.14,666.004,216.003,797.003,601.003,052.003,378.00
EBITDARs. Cr.18,176.0016,558.8813,883.0012,109.866,752.415,020.75
PBTRs. Cr.15,141.004,548.004,167.003,172.003,254.003,476.00
PATRs. Cr.10,912.003,368.003,117.002,278.002,149.002,903.00
EPSRs. Cr.45.5014.0013.009.509.0012.10
Profit & Loss Account
IndicatorUnitTTMMar 25Mar 24Mar 23Mar 22Mar 21
IncomeRs. Cr.58,930.0054,543.4849,851.0444,520.2039,576.0034,333.66
ExpenseRs. Cr.40,113.5040,113.5038,268.8334,940.3230,527.8627,228.15
Op.ProfitRs. Cr.13,229.0012,018.459,972.178,945.913,687.162,105.28
EBITDARs. Cr.18,176.0016,558.8813,883.0012,109.866,752.415,020.75
PBTRs. Cr.15,141.004,548.004,167.003,172.003,254.003,476.00
PATRs. Cr.10,912.003,368.003,117.002,278.002,149.002,903.00
EPSRs. Cr.45.5014.0013.009.509.0012.10
DividendRs. Cr.3,613.973,613.972,898.162,519.302,158.911,559.06
Balance Sheet
IndicatorUnitTTMMar 25Mar 24Mar 23Mar 22Mar 21
Share CapitalRs. Cr.239.93239.93239.93239.93239.93239.93
ReservesRs. Cr.71,978.0971,978.0963,426.8255,755.4547,771.2946,222.85
Net WorthRs. Cr.72,218.0272,218.0263,666.7555,995.3848,011.2246,462.78
ST BorrowingsRs. Cr.1,867.111,867.112,844.366,197.88700.772,444.90
LT BorrowingsRs. Cr.2.522.521.330.00229.92898.13
Fixed AssetsRs. Cr.20,290.8220,290.8219,966.3120,680.5717,197.0916,832.17
Current LiabilitiesRs. Cr.18,194.2118,194.2116,984.4019,907.0017,200.5516,145.63
CashRs. Cr.11,331.6211,331.6210,520.685,770.295,033.356,445.51
Current AssetsRs. Cr.52,624.4752,624.4743,474.9839,883.3435,014.9830,442.08
Total AssetsRs. Cr.92,100.5892,100.5885,462.8880,743.5969,799.8767,666.73
Cash Flow Report
IndicatorUnitTTMMar 25Mar 24Mar 23Mar 22Mar 21
Net Cash From Oprn.Rs. Cr.14,072.0914,072.0912,134.984,959.338,984.546,170.37
Net Cash From InvestingRs. Cr.-5,306.16-5,306.16-690.20-7,943.68-5,724.74536.22
Net Cash From FinancingRs. Cr.-7,905.82-7,905.82-6,710.162,376.07-5,193.46-5,980.48